Drug Trial Radar · NCT07520006
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
May 2033
Study completion May 2033
Sponsor
- Lead sponsor
- Nurix Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Conditions
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
NX-5948Drug
Administered orally once daily as a capsule
venetoclaxDrug
Administered orally once daily as a tablet per prescribing information
rituximabDrug
Administered as an intravenous (IV) infusion per prescribing information
obinutuzumabDrug
Administered as an IV infusion per prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse eventsTime frame: Up to approximately 7 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Not yet recruiting
Rocky Mountain Cancer Centers
Aurora, Colorado · Recruiting
University of Miami
Coral Gables, Florida · Not yet recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Not yet recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Not yet recruiting
New Jersey Cancer Care
Belleville, New Jersey · Not yet recruiting
Oncology Associates of Oregon
Eugene, Oregon · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - Northeast
Tyler, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.